๐Ÿ”Ž Trials Near Me

Home โ€บ Melanoma

Melanoma clinical trials recruiting in the U.S.

197 studies for Melanoma are recruiting participants at sites across the United States.

Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.

Cities with the most studies

By state

Recently updated studies

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

RecruitingObservational studyHealthy volunteers welcome
4 Weeks โ€“ 99 Years ยท All sexes ยท Updated Oct 2, 2026 ยท NCT00040352

Evaluation for NCI Surgery Branch Clinical Research Protocols

RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Oct 2, 2026 ยท NCT00001823

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

RecruitingPhase 2
Ages 18 to 120 ยท All sexes ยท Updated Oct 2, 2026 ยท NCT05155033

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Oct 2, 2026 ยท NCT07751042

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 2, 2026 ยท NCT06270706

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 ยท All sexes ยท Updated Oct 2, 2026 ยท NCT05334069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Oct 1, 2026 ยท NCT06172478

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Oct 1, 2026 ยท NCT06365619

NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma

RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 30, 2026 ยท NCT07740941

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 29, 2026 ยท NCT07281924

A Study of BI 3810944 in Patients With Advanced Cancer

RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 29, 2026 ยท NCT07224425

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07519655

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT06961006

DESTINY-PANTUMOUR04

RecruitingObservational study
Ages 18 to 130 ยท All sexes ยท Updated Sep 25, 2026 ยท NCT07124000

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT06246916

Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT06548789

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

RecruitingPhase 2
Up to age 25 ยท All sexes ยท Updated Sep 24, 2026 ยท NCT07621614

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 24, 2026 ยท NCT06047379

Pan-tumor MRD Study

RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Sep 24, 2026 ยท NCT06605404

Intratumoral N17350 in Advanced Solid Tumors

RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 23, 2026 ยท NCT07339176

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.